Please login to the form below

Not currently logged in
Email:
Password:

The Harmony Alliance gathers to battle blood cancer

Uses its big data platform to analyse the disease

blood cellsAt the 2nd general assembly based in Berlin, Germany last week, 120 representatives from the Innovative Medicines Initiative’s (IMI) Harmony Alliance all gathered to discuss achievements and objectives surrounding blood cancer.

The alliance, which brings together 51 partners and key stakeholders from eleven European countries, uses its big data platform to better understand blood cancer and contribute to improving targeted therapies.

Michel Van Speybroeck, director of data sciences, Janssen, said: “Public and private partners are bringing together their best people, data and knowledge to solve key questions on haematological cancers.

“These challenges can only be met by applying the most advanced technology and it’s wonderful to see from the front-line how this is being shaped by the Harmony Alliance.”

The alliance aims to offer an ethical and legal framework on the use of medical data, using its new platform for analysis and defining “standard sets of outcomes”.

Article by
Gemma Jones

30th October 2017

From: Healthcare

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Lucid Group Communications Limited

WE’RE ON A MISSION To enhance patients’ lives through communication that changes behaviour and improves patient health outcomes....

Latest intelligence

Has the pandemic opened up a future of accelerated diagnosis and better care for rare disease patients?
The challenge with rare disease is in the name – it's rare, so awareness is limited and diagnosis hindered. Could a more virtual existence change this? A Medical Affairs viewpoint...
The other side of … blood cancer
To stay motivated for the fight, some patients need to feel like active players in the treatment journey, not passengers to every decision....
COVID clinical trial
COVID-19 – a catalyst for technology adoption in clinical trials
As the COVID-19 crisis disrupts clinical trials around the globe, it is also proving to be a catalyst that may transform its approach to trials for good...

Infographics